Powerful Medical Receives €40 Million IPCEI Grant — read the full story

PMcardio for Individuals logo – AI ECG reader app for healthcare professionals

AI that reads ECGs in seconds

Get instant AI-powered ECG interpretations anytime, anywhere. Trusted by over 100,000 healthcare professionals.*

* STEMI AI ECG Model (pending FDA approval) and LVEF AI ECG Model are considered investigational devices in the US. Not for clinical use.

PMcardio for Individuals mobile app showing AI ECG interpretation and STEMI detection on smartphones
PMcardio App
PMcardio App
PMcardio App
How it works

3 Simple Steps to Instant ECG Interpretation

Snap a Photo of Any 12-lead ECG

Capture an ECG from paper, screen, or upload an image from your gallery.

Smartphone scanning a 12-lead ECG paper for instant AI interpretation with PMcardio app

Detect Over 40 ECG Conditions in Seconds

Accurately detect rhythms, STEMI and other advanced ECG abnormalities.

PMcardio app interface showing STEMI alert and detected rhythm conditions from an ECG

Visualize Results with Explainability Heatmaps

See which features matter most so you can interpret ECGs with confidence.

Explainability heatmaps in PMcardio app showing confidence levels for ECG waveform features

AI That Reads ECGs in Seconds – Try for Free

Benefits

Why 100,000+ Clinicians Trust PMcardio

ECG waveform showing hidden STEMI equivalent signals detected by PMcardio

Detect Hidden STEMI Equivalents

Detect occlusive myocardial infarctions (OMIs) even without ST elevation. PMcardio’s Queen of Hearts™ AI model identifies life-threatening STEMI equivalents early.

PMcardio app screen showing AI-generated ECG heatmaps with STEMI alert

ECG AI Explainability Heatmaps (STEMI)

See why the AI flagged a result with lead-by-lead heatmaps that show which ECG features influenced the STEMI diagnosis

List of ECG diagnoses detected by PMcardio including atrial fibrillation, LBBB, and QT syndromes

36 Core Diagnoses

Covers 36 essential ECG conditions, including arrhythmias (like atrial fibrillation), conduction blocks (e.g. LBBB), heart blocks, and chamber hypertrophies.

Second Opinion Tool

Not sure if you need an emergent consult? PMcardio gives you instant, reassurance anytime, anywhere.

12 ECG Measurements

Instantly analyze heart rate, axis, P wave, PR, QRS, and QT/QTc intervals for long-term drug monitoring.

Clinically Validated in 15+ Independent Studies

Trusted by top hospitals. Backed by prospective and real-world evidence.

Join 100,000+ Clinicians Using PMcardio

Supported diagnoses

Diagnose up to 49 available conditions, Including Critical Hidden Heart Attacks.

  • Sinus bradycardia
  • Sinus rhythm
  • Sinus tachycardia
  • Paced rhythm
  • Atrial fibrillation
  • Atrial fibrillation with rapid ventricular response
  • Atrial fibrillation with slow ventricular response
  • Atrial flutter
  • Atrial flutter with rapid ventricular response
  • Atrial flutter with slow ventricular response
  • Supraventricular tachycardia
  • Suspected junctional rhythm
  • Suspected junctional bradycardia
  • Suspected accelerated junctional rhythm
  • Wide QRS rhythm
  • Idioventricular rhythm
  • Wide QRS tachycardia
  • STEMI / STEMI Equivalent
    Includes detection of STEMI equivalents (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.).
  • 1st degree AV block
  • 2nd degree AV block, type Wenckebach
  • Higher degree AV block
  • Complete right bundle branch block
  • Incomplete right bundle branch block
  • Complete left bundle branch block
  • Incomplete left bundle branch block
  • Nonspecific intraventricular conduction delay
  • Left anterior fascicular block
  • Left posterior fascicular block
  • Bifascicular block (RBBB + LAFB)
  • Bifascicular block (RBBB + LPFB)
  • Trifascicular block (RBBB + LAFB + AVBLOCK1)
  • Trifascicular block (RBBB + LPFB + AVBLOCK1)
  • Left cardiac axis deviation
  • Right cardiac axis deviation
  • Extreme cardiac axis deviation
  • Normal axis
  • Heart rate
  • P wave
  • PR interval
  • QRS duration
  • QT interval
  • Corrected QT interval (Framingham formula)
  • RR interval
  • PP interval
  • Suspected long QT syndrome
  • Suspected short QT syndrome
  • Suspected atrial enlargement
  • Suspected ventricular hypertrophy
  • Premature complexes
Clinical evidence

Proven Impact. Measurable Results.

See how PMcardio outperforms standard care in real clinical settings with up to 2× higher sensitivity in detecting heart attacks. Validated in 15+ external, independent studies.

Bar chart showing PMcardio’s 94% sensitivity versus 43% for standard care in detecting heart attacks
Comparison chart of rhythm condition detection: PMcardio at 95% versus standard care at 82%
Bar chart showing PMcardio’s 87% detection rate for heart blocks versus 62% with standard care
Compliance and security

Meets Global Standards for
Safety, Privacy & Performance

PMcardio App

EU MDR CE Mark

PMcardio App

GDPR

PMcardio App

UK MHRA Registration

PMcardio App

AWS Foundational Technical Review

PMcardio App

ISO 13485

PMcardio App

IEC 62366

PMcardio App

IEC 80001

PMcardio App

ISO 27001

PMcardio App

IEC 62304

PMcardio App

ISO 14971

PMcardio App

IEC 82304

PMcardio App

Plus Other Controls

Health System Implementations

Used by more than 30 EU health systems leveraging AI to streamline cardiac care and improve patient outcomes

Map showing over 30 hospitals in the US and Europe using PMcardio with performance outcomes like increased sensitivity and reduced D2B times

Try PMcardio for Free

Join 100,000+ clinicians already using PMcardio to detect heart conditions with AI-powered accuracy. Get instant access to PMcardio, designed for speed, simplicity, and clinical confidence.

No credit card required

5 FREE ECGs/month

Works with any 12-lead ECG image

Smiling female doctor holding a smartphone displaying the PMcardio ECG report interface
PMcardio for Organizations

Enterprise benefits for institutions

Deploy PMcardio institution‑wide to standardize interpretation of 12‑lead ECGs. The Enterprise plan adds multi‑site administration, direct device & EHR integrations, and real‑time cardiology alerts. Driving faster, evidence‑based care across your entire network.

Unlimited Users, Locations and Report History

Access all ECGs in your organization through a single admin dashboard.

PMcardio enterprise dashboard showing ECG reports, user info, and report filters

ECG Device Integrations & Web Platform

Efficiently administer team members and control their access permissions.

PMcardio interface shown across ECG devices, smartphones, and desktop platforms

Notifications and Care 
co-ordination

Ensure timely patient management through accurate cardiology consults

Critical STEMI alert notification from PMcardio on mobile phone with patient and time details
FAQ

Frequently Asked Questions

PMcardio offers CE-certified AI ECG Models that read ECGs and offers a complex assessment of 40+ cardiac abnormalities. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care.

Certain AI ECG Modules are CE-marked medical devices under EU MDR and only certified for marketing in the European Union and the United Kingdom. Powerful Medical technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

Yes, your encrypted data never leaves your region. PMcardio is fully GDPR and HIPAA compliant and adheres to the strictest regulatory and security frameworks, including SOC 2 and ISO 27001 certifications.

For a detailed overview of our compliance, data protection practices, and security protocols, visit our Trust Center.

Yes, PMcardio’s AI ECG Models have been rigorously validated in more than 15 independent, peer‑reviewed clinical studies. Across these studies, PMcardio AI ECG interpretation outperformed standard‑of‑care methods, delivering:

  • 2x sensitivity for early STEMI detection (often on the very first ECG)
  • Reduces false STEMI alarms by over 60%, preventing false positive cath lab activations
  • Identifies atrial fibrillation (and other arrhythmias) with 98.3 % accuracy – on par with board‑certified cardiologists

For more information, the latest published evidence, and ongoing RCTs, please visit our Research page.

PMcardio supports every commercially available 12-lead ECG, whether as a single-page image or a multi-page report.

The only hard requirement is that the ECG (including all its leads) must be printed on electrocardiogram graph paper, where every five small (1 mm) squares, you can find a heavier line forming a larger 5 mm square — this is essentially the standard ECG paper. The entire ECG should appear on one continuous grid, meaning it should not be split across multiple intersecting grids. Additionally, the image must contain only the relevant leads, without any leads from other ECGs intruding into the picture.

Fewer-lead ECGs, such as 1-lead, 3-lead, or 6-lead recordings, are currently not supported.

PMcardio’s AI-powered ECG algorithms recognise 49 distinct patterns across four major categories:

  • Rhythms & arrhythmias: Atrial fibrillation/flutter, supraventricular or ventricular tachycardia, sinus bradycardia/tachycardia
  • Conduction disorders: Left/right bundle-branch block, second- and third-degree AV block
  • Ischaemia & infarction: Acute ST-elevation myocardial infarction (STEMI) and STEMI equivalents
  • ECG measurements: QTc, PR, QRS and nine additional measurements

Looking for the full, continuously updated list? Navigate to the Full List of ECG abnormalities Detected by PMcardio AI.

No. PMcardio’s AI ECG Models are deterministic, CE-certified medical devices, purpose-built for ECG interpretation, not a conversational large language model (LLM).

  • Zero hallucinations: The same ECG file always returns the same diagnosis.
  • Evidence-based training: Fixed model weights are derived from 4 million+ clinically labelled ECGs with matched patient outcomes.
  • Independent proof: Performance has been independently validated in 15 peer-reviewed validation studies across Europe and the U.S.
  • Regulatory oversight: Post-market surveillance and quality-management systems ensure ongoing compliance with Medical Device Regulation.

Learn more about how PMcardio compares to AI chatbots like ChatGPT.

Yes. In six peer-reviewed studies, PMcardio’s AI ECG algorithms has demonstrated up to 2x higher accuracy than conventional ECG algorithms used in standard ECG machines (e.g., GE Marquette 12SL, Philips, Glasgow Algorithm).

Learn more about how PMcardio compares to Conventional ECG Algorithms.

Yes. Start with a Free Plan that lets you analyse up to 5 ECGs per month at no cost. If you need more reports and advanced Pro features, you can upgrade to a paid subscription with:

  • Larger monthly ECG quota: run as many studies as your workflow demands.
  • AI explainability for STEMI: colour-coded highlights show the waveform segments driving each positive diagnosis.
  • 12 validated interval measurements: instant PR, QRS, QTc intervals and more.
  • 30-day report history: revisit, download, or share any ECG analysed in the past month.

🔗 Try PMcardio for free — available now on the Apple App Store and Google Play Store*

* Certain AI ECG Modules are CE-marked medical devices under EU MDR and only certified for marketing in the European Union and the United Kingdom. Powerful Medical technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

PMcardio in the spotlight

Smartphone displaying RCEM Learning podcast episode “September 2025” featuring discussion of PMcardio’s Queen of Hearts™ AI outperforming doctors in ECG interpretation

Can AI Outperform Doctors in ECG Interpretation? (RCEM Learning Podcast, by Dr. Andy Neill and Dr. Dave McCreary)

19. September 2025
Smartphone showing This Week in Cardiology podcast episode featuring PMcardio Queen of Hearts™ AI outperforming physicians in ECG interpretation

AI vs MD ECG-Reading for Cath Lab Activation (This Week in Cardiology, by Dr. John Mandrola)

1. August 2025
Smartphone displaying ACEP Frontline podcast episode “They’re Takin’ our Jobs – AI in Emergency Medicine” featuring discussion of PMcardio’s Queen of Hearts™ AI for ECG interpretation

‘They’re Taking’ our Jobs’ – AI in Emergency Medicine with Dr. Henry Pitzele (ACEP Frontline, by Dr. Ryan Stanton)

21. July 2025

All Supported ECG Findings

Rhythms
Sinus bradycardia • Sinus rhythm • Sinus tachycardia • Paced rhythm • Atrial fibrillation
Atrial fibrillation with rapid ventricular response • Atrial fibrillation with slow ventricular response • Atrial flutter • Atrial flutter with rapid ventricular response • Atrial flutter with slow ventricular response • Supraventricular tachycardia • Suspected junctional rhythm • Suspected junctional bradycardia • Suspected accelerated junctional rhythm • Wide QRS rhythm • Idioventricular rhythm • Wide QRS tachycardia

Myocardial Infarctions
  • STEMI
  • STEMI
    Equivalent
Detects occlusive myocardial infarctions (OMIs) even without ST elevation (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.)
  • High-Risk NSTEMI
    Represents a type 1 myocardial infarction caused by a transiently recanalized coronary occlusion—classically seen in patterns such as Wellens type A or B due to subtotal LAD obstruction, but possible in any infarct-related territory.
  • Culprit Detection
    AI-predicted likelihood scores for LAD, LCx, and RCA with 3D heart visualization highlighting the predicted culprit artery.

Conduction Abnormalities (Heart Blocks
1st degree AV block • 2nd degree AV block, type Wenckebach • Higher degree AV block • Complete right bundle branch block • Incomplete right bundle branch block • Complete left bundle branch block • Incomplete left bundle branch block • Nonspecific intraventricular conduction delay • Left anterior fascicular block • Left posterior fascicular block • Bifascicular block (RBBB + LAFB) • Bifascicular block (RBBB + LPFB) • Trifascicular block (RBBB + LAFB + AVBLOCK1) • Trifascicular block (RBBB + LPFB + AVBLOCK1)

LVEF
Reduced LVEF (≤40%) • Mildly reduced LVEF (41 – 49%) • No signs of reduced LVEF (≥50%)

Axis
Left cardiac axis deviation • Right cardiac axis deviation • Extreme cardiac axis deviation • Normal axis

Measurements
Heart rate • P wave • PR interval • QRS duration • QT interval • Corrected QT interval (Framingham formula) • RR interval • PP interval • ST elevations

Other Supported Diagnoses
Suspected long QT syndrome • Suspected short QT syndrome • Suspected atrial enlargement • Suspected ventricular hypertrophy • Premature complexes

Dr. Tom De Potter, MD

Cardiologist at the Cardiac Center Aalst

Cardiologist specializing in Pacemaker Device Therapy and Electrophysiology. Leads the electrophysiology unit at the Heart Center in Aalst, holds an executive board position at the European Heart Academy, and serves as EHRA scientific program committee co-chair.

Dr. Martin Penicka, MD, PhD

Cardiologist at the Cardiac Center Aalst

Cardiologist at the Cardiac Center Aalst since 2009, specializing in non-invasive imaging and valvular disease. Fellow of the European Society of Cardiology (FESC) and the European Association of Cardiovascular Imaging (FEACVI).

Dr. Ward Heggermont, MD, PhD

Co-director at the Cardiovascular Center

Co-director at the Cardiovascular Center of Aalst Hospital, specializing in heart failure. Research focus at the intersection of cardiology, virology, and metabolism.

Prof. Dr. Robert Hatala, PhD

Co-founder and Chief Scientist

Head of the Arrhythmia and Pacing department at the National Institute of Cardiovascular Diseases in Slovakia. More than 150 publications and 10,000 citations. Contributor to ESC clinical practice guidelines and executive editor of the European Heart Journal since 2020.

Arieh Levy

Head of PMcardio for Individuals

Arieh leads the PMcardio for Individuals product at Powerful Medical, guiding its development as a clinical tool for emergency physicians, cardiologists, and primary care physicians. He holds a First Class MEng in Biomedical Engineering from Imperial College London, where he specialised in AI for cardiology, building physics-informed neural networks to model atrial electrical properties, giving him a background that bridges the clinical and technical demands of building a certified AI medical device used at the bedside every day.

Dr. Dave Pearson, MD​

Business Advisor

Academic emergency medicine physician, entrepreneur, investor, and researcher with nearly two decades at Atrium Health, one of US largest health systems. Brings expertise at the intersection of clinical care, healthcare innovation, and strategic leadership.

Prof. Stephen W. Smith, MD

Professor of Emergency Medicine

Faculty physician in Emergency Medicine at Hennepin County Medical Center and Professor of Emergency Medicine at the University of Minnesota. Co-inventor of the OMI paradigm and editor of Dr. Smith’s ECG Blog, the most-visited US-based ECG interpretation blog.

Prof. Emanuele Barbato, MD, PhD

President of EAPCI

Interventional cardiologist specializing in coronary artery disease and coronary physiology. Acting president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and contributor to the clinical practice guidelines for STEMI care.

Scott Sharkey, MD

Chief Medical Officer

Chief Medical Officer of the Minneapolis Heart Institute Foundation and practicing cardiologist at Allina Health Minneapolis Heart Institute. Co-founder of the STEMI Midwest consortium and Takotsubo cardiomyopathy research program and a widely published clinical investigator in STEMI care.

Prof. Dr. Leor Perl, MD

Director of Cardiac Catheterization Institute

Director of Complex Cardiac Interventions and Chief Innovation Officer at Rabin Medical Center. Graduate of the Stanford Biodesign Program.

Suzanne J. Baron, MD, MSc

Director of Interventional Cardiology Research

Director of Interventional Cardiology Research at Massachusetts General Hospital. Holds a Master’s degree in health economics from Harvard School of Public Health. Expert in cardiovascular device impact on healthcare costs and patient-reported outcomes.

Prof. Marco Valgimigli, MD

Deputy Chief Cardiocentro Ticino Institute

Head of Cardiology at Cardiocentro Ticino and Principal Investigator of the TITAN-OMI randomized controlled trial. His research has shaped both European and US clinical practice guidelines on coronary stents, antithrombotic therapy, and vascular access.

Timothy D. Henry, MD

Medical Director of The Carl and Edyth Lindner Center

Leading expert in interventional cardiology and STEMI treatment. Co-founder and principal investigator of the Midwest STEMI Consortium, a registry of more than 20,000 consecutive STEMI activations. Presenting author for the TCT 2025 Late-Breaking Clinical Science on Queen of Hearts.

Matus Horvath

Head of People

Matus leads hiring strategy and culture at Powerful Medical. He previously ran the People Team at Slido, the Slovak SaaS startup later acquired by Cisco — an experience that informs how he builds a high-performing, values-driven team through rapid scaling.

Dr. Timea Kisova, MD

Clinical Research Lead

Timea leads Powerful Medical’s global external validation studies, including the multi-country AI ECG TIMI Study. With a background in biomedical sciences and a medical degree from Barts and The London School of Medicine and Dentistry, she brings the clinical discipline required to generate the prospective, real-world evidence behind every PMcardio module.

Dr. Anthony Demolder, MD, PhD

HF Pathway Lead

Research physician with a PhD on arrhythmias in heritable thoracic aortic disease. He has led international studies at the intersection of cardiology and AI — including earlier work on atrial fibrillation at AZ Sint-Jan Brugge — and now drives Powerful Medical’s heart failure pathway and LVsense™ AI model development.

Dr. Pendell Meyers, MD

ACS Pathway Lead

Emergency medicine physician, prolific educator, and Co-Editor of Dr. Smith’s ECG Blog. He is one of the leading voices behind the Occlusion Myocardial Infarction (OMI) paradigm, the clinical framework that reshaped how heart attacks are identified from the ECG — and which sits at the core of the Queen of Hearts™ model.

Adam Dej

Head of PMcardio for Organizations Engineering

Adam leads engineering for PMcardio for Organizations at Powerful Medical, driving platform architecture, backend systems, and infrastructure behind one of the company’s key growth products. He began programming at 13, entered professional IT at 17, and studied computer security at Comenius University’s Faculty of Mathematics, Physics and Informatics. Known for technical depth across distributed systems, infrastructure, and security, he builds scalable and resilient software with a sharp focus on customer impact. He also champions responsible use of AI and LLMs as force multipliers for modern engineering teams.

Gabriela Rovder Sklencarova

Head of Infrastructure

Gabriela designs the scalable, secure, distributed systems that keep PMcardio running around the clock for clinicians worldwide. She joined from Google, where she was a senior software engineer building core libraries that kept Google’s services resilient against billions of requests, and holds a BA and MA in Computer Science from the University of Cambridge.

Arezou Azar

US and Global Regulatory

Arezou leads Powerful Medical’s global regulatory strategy across the FDA, EU MDR, and international frameworks. She has been part of nearly every major breakthrough in AI cardiology and is an expert in US and global regulatory strategy, SaMD/digital health launches, with experience at Eko Health, Verily, AliveCor, Cardiologs, and Apple. She specializes in regulatory strategy in high-paced global organizations.

Adam Rafajdus

Head of AI

Adam grew into the Head of AI role from MLOps Engineer over six years at Powerful Medical, bringing deep expertise in deep learning and production-grade system deployment. He leads the team behind the Queen of Hearts™ AI ECG models and was awarded Best Poster at ISCE 2025 for the company’s ECG digitization pipeline.

Mike Wall

VP of Sales

Mike brings more than twenty years at UnitedHealth Group to the table, where he served health plans, employer groups, and public-sector entities as a consultative healthcare sales executive. He combines market intelligence, clinical insight, and financial acumen — the three ingredients needed to bring AI-powered diagnostics into US health systems at scale.

Amani Farid

Head of Strategic Partnerships

Amani leads partnership strategy with a hands-on approach to integration, unlocking long-term value through collaboration and scale. A University of Chicago Law School-trained attorney and former M&A and capital markets associate at two top international law firms, she brings the rare combination of legal precision and commercial execution refined across nearly a decade at Stryker and as VP of Corporate Development at RapidAI — spanning medtech, digital health, and AI-driven diagnostics.

Michal Martonak

Commercial Lead

A mathematician by training, Michal leads commercial strategy, go-to-market, and strategic partnerships with healthcare providers and clinical institutions worldwide. He previously built Powerful Medical’s data and clinical partnerships function, acquiring the large-scale clinical datasets that underpin the company’s certified AI models.

Dr. Jozef Bartunek, MD, PhD

Co-founder and VP Clinical Strategy

Interventional cardiologist and Co-director of the Cardiovascular Center in Aalst, Belgium — one of the world’s leading heart centers. A Fogarty International NIH Fellow at Harvard Medical School and visiting Professor of Medicine at Catholic University Leuven, he has authored more than 240 peer-reviewed publications in heart failure and structural heart disease, and anchors Powerful Medical’s clinical and research strategy.

Simon Rovder

Co-founder and CTO

Simon began his engineering career at Microsoft and holds a Master’s degree in Informatics from the University of Edinburgh. He built and scaled Powerful Medical’s technology organization from the ground up to a team of 20+ engineers, leading the architecture of a CE-certified Class IIb medical device now deployed in hospitals across Europe.

Viktor Jurasek

Co-founder and CPO

Viktor was modding computer games before his teens and has spent the last decade shipping digital products across advertising, finance, and healthcare. As co-founder and CPO, he has led PMcardio’s product and design since the first prototype, setting the bar for how a clinical-grade tool should feel in a physician’s hands — fast, clear, and trustworthy at the point of care.

Felix Bauer

Co-founder and COO

Felix was part of the Hyperloop team that repeatedly competed and won in Elon Musk’s SpaceX Hyperloop Pod Competition. He holds a degree from the Technical University of Munich and brings a rare combination of engineering rigor, regulatory discipline, and operational excellence to the company, spearheading operations, compliance, regulatory, quality management, and global market access since day one.

Dr. Robert Herman, MD, PhD

Co-founder and Chief Medical Officer

Robert is a physician-scientist who served on the Research, Digital and Innovation Committee of the European Society of Cardiology. He bridges medicine and AI, connecting clinicians, researchers, regulators, and trial leaders to translate algorithms into clinical practice. He founded multiple AI ECG models, leads international clinical trials validating them, is a recipient of the Journal of the American College of Cardiology Spencer King Award, and was named to Forbes 30 Under 30 Europe 2024.

Martin Herman

Co-founder and CEO

Martin started coding at 14 and moved to Silicon Valley at 18, founding several companies including a US-based startup before returning to Europe with his brother Robert to build Powerful Medical. He comes from a family of doctors, which shaped his conviction that AI belongs wherever it can genuinely save lives. Forbes 30 Under 30 (Europe 2024).

Heart Attacks are #1 cause of death world-wide and killing about 12 milions people a year.

Clinical Definition of Problem

Contrary to popular belief, a heart attacks isn’t a blockage inside of the heart. A heart attack is a blockage of the coronary arteries supplying the heart muscle with oxygenated blood.

So let’s assume you get a blood clot here — it blocks the blood flow downstream, meaning the heart muscle doesn’t get oxygenated blood and heart tissue downstream starts to die.

Clinical Solution​

The way to fix it is relatively simple – doctors put in a stent that opens up the artery and renews blood flow. The latest clinical practice guidelines recommend that this “stenting” happens within 90 minutes from symptom onset.

If you don’t, even if you put in the stent in later, the heart tissue downstream has already been permanently damaged, which reduces the heart’s ability to pump blood. This is the leading cause of heart failure and increases 1-year mortality by two-fold.

Time is muscle.

You have just 90 minutes to diagnose the patient, bring them to the hospital and put in the stent, otherwise there is permanent damage. So problem is, that 1 in 2 heart attacks get initially misdiagnosed at the first point of contact.

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.